#NewsSpeak: FDA needs more time to assess ocrelizumab

People with primary progressive MS will have to wait a little longer. #MSBlog #NewsSpeak

The FDA has delayed their decisions on ocrelizumab; not the sort of news people with MS want to hear days before Christmas. However, I have been assured the delay is simply to buy the FDA more time to assess new data. We all remain confident that the FDA will license ocrelizumab for both relapsing-forms of MS and PPMS.

Press release: Roche announced today that the FDA has extended its review for ocrelizumab until the 28th March 2017. The extension is the result of the submission of additional data by Roche regarding the manufacturing process of ocrelizumab, which required additional time for FDA review. Roche have stated that the extension is not related to the efficacy or safety of ocrelizumab.

CoI: multiple

About the author

Prof G

Professor of Neurology, Barts & The London. MS & Preventive Neurology thinker, blogger, runner, vegetable gardener, husband, father, cook and wine & food lover.


By Prof G



Recent Posts

Recent Comments